HIV drug resistance: brief report 2024
This brief report summarizes recent information on HIV drug resistance (HIVDR) in the era of integrase-strand transfer inhibitors (INSTI) for HIV prevention and treatment. In this report, WHO documents
AIDS
-
Pact signed on use of HIV treatment drug
The International Partnership for Microbicides (IPM) has signed an agreement with pharmaceutical company Pfizer under which the pharma major will give IPM a royalty-free license to use maraviroc, its newly approved HIV treatment, as a microbicide for the prevention of HIV infection. Maraviroc is one of a new class of antiretroviral drugs which works to prevent HIV infection by preventing the virus from gaining entry into target cells. "The drug's safety and efficacy data as a therapeutic will speed its development as a microbicide. This agreement adds a promising new compound to IPM's pipeline allowing us to explore new ways to prevent infection,' Zeda Rosenberg, CEO of the IPM told The Hindu here on Wednesday. Microbicides are products, such as gels, films and rings that could be applied vaginally to prevent transmission of HIV during vaginal intercourse. IPM is also developing other delivery methods such as long-last vaginal rings that release drug gradually over time. Under this agreement, IPM would work to develop maraviroc as a vaginal microbicide with the right to develop, manufacture and distribute the microbicide in developing countries that would reduce the cost of the end product and make it accessible to women in the developing countries, Ms Rosenberg said. Trials continue Admitting that the first general of microbicides products did not seem to work well, Ms Rosengerg said the good news was that large scale efficacy trials for the second generation of microbicides were on, and if successful, would be available in the market in the next five years. Results from the second IPM dapivirine ring study have shown that the reservoir vaginal ring was safe and well tolerated by women after seven days of use. IPM has finalised a protocol for a placebo vaginal ring safety and acceptability study to be conducted in Kenya, South Africa and Tanzania. The study, initiated in early 2007, will include 200 female participants and will generate critical data on the needs and preference of women and their male partners, in preparation for the eventual introduction of and access to microbicides among user population.
-
The global aids fight
Congress and the White House are preparing to ramp up spending on programs to combat AIDS and related diseases around the world while removing some of the ideological blinders that have long undermine
-
Japan gives $184 mil to Global Fund for AIDS, tuberculosis, malaria
Japan will provide $184 million of fresh aid to the Global Fund to Fight AIDS, Tuberculosis and Malaria, Foreign Minister Masahiko Komura said Friday. This will bring Tokyo's total contribution to $850 million since the fund was established in 2002 to combat the three diseases that kill 5 million people each year, according to the Foreign Ministry. The fund, created as a result of discussion by leaders at the G-8 summit in Okinawa in 2000, has supported a total of 524 projects in 136 countries.
-
Bank's world
some of India's critical public health schemes have a long track record of corruption. The World Bank has a long record of hiring expensive consultants to tell us so. In this cynical theatre arrives
-
HIV infections hit record 1,048 in Japan in 2007
The number of people reported infected with HIV in a year in Japan reached a record high of 1,048 in 2007, while that of people reported to have developed AIDS came to 400, bringing the total to 1,448, preliminary data released Tuesday by the government's AIDS Surveillance Committee showed.
-
Scientists find new HIV receptor
SAN FRANCISCO, FEBRUARY 11: US Government scientists have discovered a new way that HIV attacks human cells, an advance that could provide fresh avenues for the development of additional therapies to stop AIDS, they reported on Sunday. The discovery is the identification of a new human receptor for HIV. The receptor helps guide the virus to the gut after it gains entry to the body, where it begins its relentless attack on the immune system.
-
Good bacteria can fight HIV transmission
Abeneficial bacteria, widely found in yogurt, might help the scientists to stop or slow down HIV transmission rate, a recent study has revealed. The research, presented at the Conference on Retroviruses and Opportunistic Infections in Boston this week, was conducted by physicians and scientists of the University of Washington and the University of Rochester Medical Centre to learn more about how the HIV virus survives and spreads from person to person.
-
Hotline for HIV concerns
In a small room, in a modest, but well-maintained building in Central Cairo, a phone rings. The caller, a woman, suspects that her husband has been having sex with someone else. She is concerned that
-
Human health and forests: a global overview of issues, practice and policy
Hundreds of millions of people live and work in forests across the world. One vital aspect of their lives, yet largely unexamined, is the challenge of protecting and enhancing the unique relationship between the health of forests and the health of people.
-
Towards universal access: scaling up priority HIV/AIDS interventions in the health sector
The objective of this report is to monitor global progress in the health sector as it scales up HIV prevention, treatment and care interventions towards universal access . The current report is the second in a series of annual progress reports developed by the WHO, the joint UNAIDS and the UNICEF in partnership with other international monitoring and reporting mechanisms to monitor the response of the health sector to HIV. This report includes a focus on women and children.